Skip to content

IVM Versus IVF in High Antral Follicle Count Patients

The Effectiveness and Safety of in Vitro Maturation of Oocytes Versus in Vitro Fertilization in Women With High Antral Follicle Count (AFC): a Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03405701
Enrollment
546
Registered
2018-01-23
Start date
2018-01-25
Completion date
2019-12-03
Last updated
2019-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF, IVM, PCOS

Brief summary

In vitro maturation (IVM) is postulated to be an alternative to conventional in vitro fertilization (IVF) to avoid ovarian hyperstimulation syndrome. This has particular potential in women with Polycystic Ovarian Syndrome (PCOS), who are at increased risk for the ovarian hyperstimulation syndrome. However, no randomized controlled trials on the comparison of IVM and conventional IVF in women with PCOS have been reported with respect to pregnancy rate and hyper-stimulation. Investigators aim to compare the effectiveness and safety of IVM with controlled ovarian hyperstimulation/IVF in women with high antral follicle count.

Detailed description

Women with PCOS and PCOM or high AFC: ≥24 Antral Follicles in Both Ovaries will be given the information about the study during the first consultation which is at least 2 weeks before having periods. On the second day of periods, women will be screened for eligibility by the treating clinicians. Women who met the inclusion criteria will be invited to participate in the study. Women will be randomized (1:1) to IVM or IVF- GnRH agonist triggering cycle using block randomization by an independent study coordinator via telephone, using a computer-generated random list (block size 2, 4, 6 or 8). Group 1: IVM Patients with a normal cycle length (\>/=35 days) will receive injected highly purified human menopausal gonadotropin (hp-hMG; Menopur, Ferring) 150 IU/day starting on day two or three of the spontaneous menstrual cycle. Oocyte retrieval will be performed 42 hours after the last hp-hMG injection. Women who do not have a normal cycle length (\>35 days; 4-9 menstrual cycles in a year or amenorrhea) will take an oral contraceptive for 2 weeks, then receive hp-hMG 150 IU/day (hp-hMG; Menopur, Ferring injection for 2 days starting 5 days later. In all patients, ultrasound will be performed on the second day of gonadotrophin injection and OPU is scheduled for 42 hours after the last gonadotrophin injection. After oocyte pick-up, all oocytes will be placed in pre-maturation medium (CAPA Pre-maturation in Medicult IVM medium, Origio, Denmark) for 24 hours, then transferred to maturation culture (Medicult IVM system with phenol red, Origio, Denmark) for 30 hours. Group 2: IVF All women in this group will undergo COH using a hp-hMG/GnRH antagonist protocol, with an hp-hMG dose of 150-225 IU/day (Menopur, Ferring), depending on age and body mass index. Follicular development will be monitored using ultrasound scanning, and estradiol and progesterone levels. When at least two leading follicles reach 17 mm in diameter, GnRH agonist (GnRHa) triggering with triptorelin 0.2 mg (Diphereline, Ipsen Beaufour) will be administered, and oocyte retrieval performed 36 hours later. Laboratory procedures For both groups, insemination will be performed using intra-cytoplasmic sperm injection (3-4 hours after oocyte retrieval or maturation check); only matured oocytes will be inseminated. Fertilization check will be performed under an inverted microscope at 16-18 hours after insemination. Embryo evaluation will be performed at 68 ±1 hours after fertilization using the Istanbul consensus. Freeze-all and Frozen embryo transfer In both groups, all embryos will be frozen on day 3. Frozen transfer of a maximum of 2 embryos will be performed in a subsequent cycle using HRT for endometrial preparation. In the following cycle, the endometrium will be prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day starting from the second or third day of the menstrual cycle. Endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Cyclogest®; Actavis) 800 mg/day will be started when endometrial thickness reached 8 mm or more. A maximum of 2 embryos will be thawed on the day of embryo transfer, three days after the start of progesterone. Two hours after thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. When women had more than two embryos frozen, the procedure will be repeated in subsequent cycles if they fail the first transfer.

Interventions

PROCEDUREIVM

Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.

PROCEDUREIVF

Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.

Sponsors

Mỹ Đức Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women with high AFC (≥24 Antral Follicles in Both Ovaries), including PCOS plus PCO or high AFC * Having indications for ART * Having ≤ 2 IVM/IVF attempts * Permanent resident in Vietnam * Agree to have all embryos frozen on day 3 * Agree to have ≤ 2 embryos transferred in a subsequent frozen transfer * Not participating in another IVF study at the same time

Exclusion criteria

* Oocyte donation cycles * Pre-implantation genetic diagnosis (PGD) cycles

Design outcomes

Primary

MeasureTime frameDescription
Live birth after the first embryo transfer of the started treatment cycle12 weeks of gestationLive birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twins will be a single count). To allow assessment of the timing of live birth, the rate of ongoing pregnancy at 12 weeks will be used in calculations, conditional on the fact that this ongoing pregnancy results in live birth.

Secondary

MeasureTime frameDescription
Clinical pregnancy5 weeks after embryo placement after the completion of the first transferat least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity
Ongoing pregnancyat 10 weeks or beyond after the embryo placement after the completion of the first transferPregnancy with detectable heart rate at 12 weeks' gestation or beyond
Implantation rate3 weeks after embryo transferred after the completion of the first transferas the number of gestational sacs per number of embryos transferred
Number of top quality embryos3 days after oocytes pick-up day in IVF or 5 days in IVMTop quality embryos are defined followed Istanbul consensus
Positive pregnancy testat 2 weeks after the embryo placement after the completion of the first transferSerum human chorionic gonadotropin level greater than 5 mIU/mL
Time from randomisation to ongoing pregnancy12 weeks of gestation after the completion of the first transferTime from randomization to ongoing pregnancy after the completion
Cumulative ongoing pregnancy at 6 monthsat 6 months after randomizationAfter 6 months, most patients doing IVM have finished all their frozen embryos. If they still fail, they usually change to IVF. We lose the comparison; therefore, we consider this time point for analyzing the cumulative ongoing pregnancy rate.
Cumulative ongoing pregnancy at 12 monthsat 12 months after randomizationAfter 12 months, most patients doing IVF have finished all their frozen embryos; therefore, we consider this time point for analyzing the cumulative ongoing pregnancy rate.
Number of freezable embryos3 days after oocytes pick-up day in IVF or 5 days in IVM after the completion of the first transferNumber of frozen embryos

Other

MeasureTime frameDescription
Iatrogenic preterm birthat 24, 28, 32 weeks and 37 weeks of gestation after the completion of the first transferDefined as delivery at \<24, \<28, \<32, \<37 completed weeks
Birth weightat the time of deliveryWeight of singletons and twins
Large for gestational ageat the time of delivery after the completion of the first transferbirth weight \>90th percentile
Small for gestational ageat the time of delivery after the completion of the first transferbirth weight \< 10th percentile
Low birth weightat birth after the completion of the first transferWeight \< 2500 gm at birth
Very low birth weightat birth after the completion of the first transferWeight \< 1500 gm at birth
Ovarian hyperstimulation syndrome (OHSS)at 03 days after oocytes pick-up and 14 days after embryo transferRoutine assessments for OHSS were performed on day 3 post oocyte retrieval in both groups. At other times, OHSS was evaluated if symptoms were reported by the patient. OHSS was classified using the flow diagram developed by Humaidan and colleagues for use in clinical trial settings
Very high birth weightat birth after the completion of the first transferWeight \>4500 gm at birth
Congenital anomalyAt 6 months after randomisationAny congenital anomaly will be included
Admission to NICU7 days after delivery after the completion of the first transferThe admittance of the newborn to NICU
Genetic and epigenetic analysis of newborn1 day (Prior to the initiation of IVF/IVM) and 1 day ( at the time of delivery)Maternal whole blood; newborn's materials including cord blood, neonatal buccal smear, and placental tissue will be collected
Cost-effectivenessTwo year after randomizationIncluding direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.
High birth weightat birth after the completion of the first transferWeight \>4000 gm at birth
Ectopic pregnancyat 12 weeks of gestation after the completion of the first transfera pregnancy in which implantation takes place outside the uterine cavity after the completion of the first transfer
Miscarriageat 24 weeks of gestation after the completion of the first transferpregnancy loss at \< 12 weeks
Hypertensive disorders of pregnancyat 20 weeks of gestation or beyond after the completion of the first transferPregnancy-induced hypertension, pre-eclampsia and eclampsia
Gestational diabetes mellitusat 24 weeks of gestation after the completion of the first transferusing a 75g oral glucose tolerance test
Preterm deliveryat 24, 28, 32 weeks and 37 weeks of gestation after the completion of the first transferMultiple definitions, defined as delivery at \<24, \<28, \<32, \<37 completed weeks
Multiple pregnancyafter the completion of the first transferDefined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)
Multiple delivery22 weeks of gestation or beyond after the completion of the first transferBirth of more than one baby beyond 24 weeks
Antepartum haemorrhageAfter the completion of the first transferIncluding placenta previa, placenta accreta and unexplained
Spontaneous preterm birthat 24, 28, 32 weeks and 37 weeks of gestation after the completion of the first transferDefined as delivery at \<24, \<28, \<32, \<37 completed weeks

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026